- Home
- CYH vs ORIC Comparison
CYH vs ORIC Comparison
Compare CYH & ORIC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CYH
- ORIC
- Stock Information
- Founded
- CYH 1985
- ORIC 2014
- Country
- CYH United States
- ORIC United States
- Employees
- CYH N/A
- ORIC N/A
- Industry
- CYH Hospital/Nursing Management
- ORIC Biotechnology: Pharmaceutical Preparations
- Sector
- CYH Health Care
- ORIC Health Care
- Exchange
- CYH Nasdaq
- ORIC Nasdaq
- Market Cap
- CYH 410.5M
- ORIC 1.1B
- IPO Year
- CYH 1991
- ORIC 2020
- Fundamental
- Price
- CYH $4.13
- ORIC $13.34
- Analyst Decision
- CYH Hold
- ORIC Strong Buy
- Analyst Count
- CYH 8
- ORIC 8
- Target Price
- CYH $3.73
- ORIC $16.57
- AVG Volume (30 Days)
- CYH 2.7M
- ORIC 1.5M
- Earning Date
- CYH 10-23-2025
- ORIC 11-06-2025
- Dividend Yield
- CYH N/A
- ORIC N/A
- EPS Growth
- CYH N/A
- ORIC N/A
- EPS
- CYH 2.47
- ORIC N/A
- Revenue
- CYH $12,644,000,000.00
- ORIC N/A
- Revenue This Year
- CYH N/A
- ORIC N/A
- Revenue Next Year
- CYH $2.46
- ORIC N/A
- P/E Ratio
- CYH $1.67
- ORIC N/A
- Revenue Growth
- CYH 0.74
- ORIC N/A
- 52 Week Low
- CYH $2.24
- ORIC $3.90
- 52 Week High
- CYH $4.64
- ORIC $14.93
- Technical
- Relative Strength Index (RSI)
- CYH 70.52
- ORIC 56.51
- Support Level
- CYH $4.07
- ORIC $11.71
- Resistance Level
- CYH $4.43
- ORIC $13.80
- Average True Range (ATR)
- CYH 0.22
- ORIC 0.73
- MACD
- CYH 0.12
- ORIC -0.08
- Stochastic Oscillator
- CYH 81.13
- ORIC 66.29
About CYH Community Health Systems Inc.
Community Health Systems Inc is a publicly owned hospital operator in the United States. The company also owns four home health agencies and provides management and consulting services to independent hospitals. The firm derives revenue through a broad range of general and specialized hospital healthcare services and outpatient services.
About ORIC Oric Pharmaceuticals Inc.
ORIC Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It has a pipeline of therapies designed to counter resistance mechanisms in cancer by leveraging its expertise within three specific areas: hormone-dependent cancers, precision oncology, and key tumor dependencies. The company has product candidates namely ORIC-944, ORIC-114, and ORIC-533. The Company has as one operating segment, focused on the discovery and development of therapies designed to counter the resistance mechanisms in cancer.